Category Archives: Business

25Jul/19
Dassault France

Medidata: The Missing Link in Dassault Systèmes Powerful Portfolio to Support the Life-Science Industry

Dassault Systèmes Analyst Conference Brief 2019

By: Sandra K. Rodriguez, Market Analyst

The news out of this years’ Dassault Systèmes Analyst Conference was huge: a $5.8 Billion merger offer with clinical data giant, Medidata.  We received the news while traveling from our hotel to the Dassault Systèmes headquarters, nestled in Vélizy-Villacoublay, France.  Aside from the size of the deal – the largest in the history of Dassault Systèmes – Medidata was the missing link in its powerful portfolio to support the Life-Science industry.

Bernard Charlès, CEO and vice-chairman of the board of directors at Dassault Systèmes, opened the two-day meeting with, “To do ‘smart’ anything, you need to know the environment.  The platform phenomenon is not an IT topic… it’s a new way for companies to work.”  Dassault Systèmes now has 250,000 customers, with 25 million users in 140 countries.  The 3DEXPERIENCE platform currently consists of 11 brands/applications that support the ability for people and businesses to develop, collaborate and build products and services in both the virtual and real worlds.

Dassault Systèmes considers itself a Scientific company, first and foremost.   The Industry Renaissance theme of this years’ conference was explained in simple terms by Morgan Zimmermann, CEO for NETVIBES-EXALEAD (the Dassault Systèmes solution for turning large amounts of information into intelligence).  “Think of Renaissance as the new book. The book changed how we distributed knowledge; Industry Renaissance for Dassault Systèmes is the usage of experience as a new way to distribute knowledge and know-how” explained Zimmermann.

The 3DEXPERIENCE Platform offers both people and businesses, virtual universes to imagine, develop and collaborate using innovative solutions.

Life is the New Work Bench

Mentioned earlier in this brief, Medidata was the missing link in the Dassault Systèmes solution platform to support end-to-end product development in the Life-Sciences.  “Pharmaceutical and Biotech companies require roughly ten to twelve years in the R&D phase to bring a drug or therapy to market” explained Claire Biot, Ph.D., VP of Life Sciences Industry at Dassault Systèmes.  Therefore, shifting that timeline left early on in the clinical trial phase of a product adds significant value to Life-Sciences companies.

Image Courtesy of Dassault Systèmes

Image Courtesy of Dassault Systèmes – Claire Bisot.

Clinical trials are necessary to prove the safety and efficacy of a drug on not only a patient population, but the medical condition itself.

Download and read the entire Briefing Note.

15Jul/19
IASO Compilation-700x400

More Than Skin Deep: Dassault Systèmes is Transforming the Patient Experience

Dassault Systèmes 3DExperience North America 2019 Forum Event Brief

By: Daniel R. Matlis, President

At this year’s 3DEXPERIENCE North America Forum, Dassault Systèmes continued to demonstrate its commitment to transforming the patient experience.

Under the leadership of Bernard Charlès, Vice Chairman, Chief Executive Officer, the company continues to substantially deliver on the promise: “to enable innovative patient experiences through a Holistic Patient-Centric strategy.”  (Read:  Dassault Targets Life-Sciences with Mind, Body and Soul)

According to Charlès there are several concurrent themes that are impacting the Life Science industry with Bioscience playing a major role.

  • Healthcare is expensive
  • Healthcare needs to be more inclusive
  • Life-Science product development needs to take advantage of technological changes

“Dassault Systèmes is investing massively in Life Sciences to transform the patient experience with a culture of sustainable innovation and the use of cutting edge technology,” added Charles. Continue reading

08Jul/19
Jumping

Webinar: Digital Transformation Enables Review by Exception at FDI – A Case Study

A Straight from the Source Webinar Available On-Demand

Review by Exception is the ultimate goal of Electronic Batch Records (EBR) and Manufacturing Execution System (MES) implementations at Life-Science organizations. Yet few industry companies have achieved this goal.

Fujirebio Diagnostics Inc., (FDI) is undergoing Digital Transformation, starting with MES / EBR implementation, resulting in a Review by Exception approach for manufacturing batch records.

Join FDI’s Samantha Schloth and Axendia’s Daniel R. Matlis for a live webinar on August 6 at 11:00 AM ET to learn how Digital Transformation is enabling Review by Exception and reducing manufacturing cycle times.

We will discuss:

  • Undergoing Digital Transformation
  • Leveraging FDA’s Risk Based Computer System Assurance Approach
  • An Implementation Strategy for success
  • Moving from Paper to Digital Records
  • The Value of Review by Exception
  • Lessons learned, challenges and opportunities

Meet Your Trusted Sources

Sam Dan 3

Register to view the webinar on-demand.

register

28Jun/19
quartic ai logo

Artificial Intelligence Can Make Pharmaceutical Companies More Competitive

Quartic.AI Briefing Note

By: Eric M. Luyer, Industry Research Analyst

Axendia was recently briefed by the senior executive team of Quartic.ai, based in San Jose, CA, US.   Quartic.ai was founded in 2017 by veterans in process automation, manufacturing, and reliability in conjunction with data scientists to optimize the practical use of information through Artificial Intelligence (AI) deployment.  The company had been recognized last year as the fastest growing technology leader in industrial AI by CIO Review Magazine.

The mission of Quartic.ai is to enable subject matter experts (SME) to help solve manufacturing problems by using AI. “We look at this as becoming another tool in their tool-belt of problem-solving. What we’re building enables the SMEs to build their solutions with AI”, said Rajiv Anand the CEO of Quartic.ai.

According to Rajiv Anand, their vision and mandate is not to grow their business through providing services, but by providing the technology. Their technology is a complete “smart industry platform” to support process- and pharma manufacturing industries via digital transformation using the concepts of the Industrial Internet of Things (IIoT) and AI. Continue reading

13Jun/19
cropped-CQ-logo (1)

7 Reasons Life-Science Companies are Implementing eQMS in the Modern Cloud

ComplianceQuest Briefing Note

By: Sandra K. Rodriguez, Market Analyst

Axendia was recently briefed by Prashanth Rajendran, CEO, and Nikki Willett, Chief Strategy Officer, at ComplianceQuest.  The company sees multiple drivers for an up-tick in the adoption of eQMS in the Life Sciences industry, especially on a modern cloud platform:

  • Electronic Quality Management System (eQMS) as a necessity for emerging growth companies
  • Digital transformation (Quality 4.0)
  • Collaborative global regulatory bodies requiring consistent control
  • The services society demanding more managed applications
  • The power of a single platform to meet multiple business needs
  • The role of quality in merger and acquisition activities
  • Operational efficiencies are driving the top line and profitability

Historically, QMS had been targeted at managing quality/compliance documents. The transition that Axendia has noticed in the marketplace is that while companies still require documentation to support quality processes, what is more important is the underlying data that is housed in those documents. Emerging growth companies typically will focus on the product and getting the product approved…and eQMS was not always at the top of the minds of executives.  However, we’re seeing quite a bit of a change in that emerging growth companies are seeing that going electronic as early as possible is a value and an efficiency gain for them, said Willett.

Register to receive the entire Briefing Note in your inbox.